3rd Quarter 2026 Results

3rd Quarter 2026 Sales

$25.4B Worldwide increased ▲ **5.9%**

Excluding the impact of translational currency: Worldwide increased ▲ **6.0%**[1]

Stelara impacted results by ~(420) basis points

Diluted earnings per share (EPS)[3] **$0.09**

Includes the impact of one-time special charges and M&A transactions

Adjusted diluted earnings per share[1,4] **$2.59** Worldwide decreased ▼ **(7.5)%**





Joaquin Duato
Chairman & Chief Executive Officer
Johnson & Johnson

"Johnson & Johnson's strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio. In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade."

$16.8 billion Worldwide Innovative Medicine sales

Innovative Medicine worldwide reported sales increased 7.7% or 7.9% operationally[2]. Stelara impacted results[2] by ~(690) basis points. Primary operational drivers:

Tremfya (guselkumab) · DARZALEX (daratumumab) · CARVYKTI (ciltacabtagene autoleucel) · Spravato (esketamine) nasal spray · CAPLYTA (lumateperone) capsules 42 mg · TECVAYLI (teclistamab-cqyv) · RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) · Erleada (apalutamide)

$8.6 billion Worldwide MedTech sales

MedTech worldwide sales increased 2.5% reported and operationally[2]. Primary operational drivers:

- Electrophysiology
- Trauma
- Shockwave
- Contact Lenses
- Surgical Vision
- Biosurgery

Johnson&Johnson

For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson's earnings release issued on October 13, 2026 available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx

[1] Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

[2] Non-GAAP measure; excludes the impact of translational currency.

[3] Includes the impact of a one-time special charge related to the proposed talc litigation resolution, as well as expenses related to the acquisition of Firefly Bio, Inc. and strategic collaboration with Sail Biomedicines

[4] Includes expenses related to the acquisition of Firefly Bio, Inc. and strategic collaboration with Sail Biomedicines

Note: Values may be rounded

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on October 13, 2026 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.